Amneal Generics Unit Continues To Grow Following Complex Products Shift
Firm Had Raised Its 2023 Guidance Ahead Of Results Publication
Executive Summary
Amneal’s generics portfolio delivered considerable growth during Q3, as a result of its ongoing shift toward complex products and successful new launches.